U.S. markets open in 6 hours 36 minutes
  • S&P Futures

    -8.25 (-0.24%)
  • Dow Futures

    -46.00 (-0.16%)
  • Nasdaq Futures

    -21.25 (-0.18%)
  • Russell 2000 Futures

    -2.40 (-0.15%)
  • Crude Oil

    -0.29 (-0.71%)
  • Gold

    +2.00 (+0.11%)
  • Silver

    -0.00 (-0.02%)

    -0.0021 (-0.18%)
  • 10-Yr Bond

    0.0000 (0.00%)
  • Vix

    -0.54 (-1.88%)

    -0.0024 (-0.19%)

    -0.0890 (-0.08%)

    -59.18 (-0.46%)
  • CMC Crypto 200

    +4.45 (+1.74%)
  • FTSE 100

    +9.15 (+0.16%)
  • Nikkei 225

    +42.32 (+0.18%)

MyDx Announces Letter to Shareholders

SAN DIEGO, Aug. 07, 2019 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- MyDx, Inc. (OTC: MYDX), a leader in science based cannabis health technologies, today issued a press release with the following letter to shareholders.

Dear Shareholder,

I hope this letter finds you well.

I would like to take this opportunity to share with you an important status update for the company.

Unfortunately, effective August 1, 2019, Mr. Erai Beckman and Mr. Matthew Bucciero resigned from their positions as board member and CEO/CFO of MyDx, respectively.

While I must continue to honor previous obligations outside of MyDx that will prevent me from formally committing to the role of CEO/CFO at this time, I declare my full support to MyDx in order to set it on the right track to expand and prosper again with a new set plan of action.

I want to thank loyal shareholders for their continued faith and support of MyDx and reiterate my commitment to do the best I can to move the company forward.

Kind Regards,

Daniel Yazbeck

About MyDx, Inc.
MyDx, Inc. (MYDX) is a leader in science based cannabis health technology with a focus on understanding the cannabis brand preferences of consumers and patients. MyDx is working on implementing this vision by creating some of the most advanced consumer smart devices, applications, and services all working together towards creating one of the largest crowdsourced databases of consumer and patient feedback that ties physiological effects to specific cannabinoid and terpene profiles. The company believes this is the kind of database that can drive the future of medicine for the global cannabis industry.

Forward-Looking Statements
This news release contains "forward-looking statements" as that term is defined in Section 27(a) of the Securities Act of 1933, as amended, and Section 21(e) of the Securities Exchange Act of 1934, as amended. Statements may contain certain forward-looking statements pertaining to future anticipated or projected plans, performance and developments, as well as other statements relating to future operations and results. Any statements in this press release that are not statements of historical fact may be considered to be forward-looking statements. Words such as "may," "will," "expect," "believe," "anticipate," "estimate," "intends," "goal," "objective," "seek," "attempt," or variations of these or similar words, identify forward-looking statements. These forward-looking statements by their nature are estimates of future results only and involve substantial risks and uncertainties, including but not limited to risks associated with the uncertainty of future financial results, additional financing requirements, development of new products, our ability to complete our product testing and launch our product commercially, the acceptance of our product in the marketplace, the uncertainty of the laws and regulations relating to cannabis, the impact of competitive products or pricing, technological changes, the effect of economic conditions and other uncertainties detailed from time to time in our reports filed with the Securities and Exchange Commission, available at https://ir.mydxlife.com/all-sec-filings or www.sec.gov.

MyDx Shareholder Communications
800.814.4550 ext. 4